Mechanisms of resistance to BCR-ABL and other kinase inhibitors.
about
Targeting tumor-stromal interactions in bone metastasisMolecular Determinants Underlying Binding Specificities of the ABL Kinase Inhibitors: Combining Alanine Scanning of Binding Hot Spots with Network Analysis of Residue Interactions and CoevolutionNovel agent nitidine chloride induces erythroid differentiation and apoptosis in CML cells through c-Myc-miRNAs axis.Sensitization of chemo-resistant human chronic myeloid leukemia stem-like cells to Hsp90 inhibitor by SIRT1 inhibition.Genetic events other than BCR-ABL1.Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer.Translational research in oncology--10 years of progress and future prospects.NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins.Small-world networks of residue interactions in the Abl kinase complexes with cancer drugs: topology of allosteric communication pathways can determine drug resistance effects.New Abelson interactor-1 (Abi-1)-driven mechanism of acquired drug resistance.Enhancing Virtual Screening Performance of Protein Kinases with Molecular Dynamics SimulationsInhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.Atomic view of the energy landscape in the allosteric regulation of Abl kinase.Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348).Posttranscriptional Regulation of PARG mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors.The SH2 domain of Abl kinases regulates kinase autophosphorylation by controlling activation loop accessibility.Ponatinib-induced neutrophilic panniculitis.Ponatinib Activates an Inflammatory Response in Endothelial Cells via ERK5 SUMOylationBCR-ABL exon 7 deletion and novel point mutation in patient with chronic myelogenous leukemia and TKI resistance
P2860
Q27024561-DD588011-8D01-4A16-A106-4CE252486151Q28548366-FD7754AE-EFE8-4379-80F1-4057C5EBBB38Q35554311-C2786181-746F-4AF9-80F6-20BD40466181Q35830047-489DAA0B-159B-4D9A-9D28-2385EDBBCCF8Q38177162-1A3A9097-CB55-4D81-A778-BAEC52778F46Q38238613-C0BA05E0-D330-4771-A474-F39C45BC78C0Q38257126-0B1015C1-1449-459F-8483-1AB9400C6BC6Q39122858-4C08FDF7-AEDC-4FCB-A7D5-290DDFC8C15EQ39277365-24B59D38-E776-4ED0-9089-3C6668AC3C40Q40819781-99AC9015-D826-432A-B55C-E0788593C470Q42320200-FD53C268-11AA-44E8-903C-96140B801DC6Q42412981-A16F9313-3F40-4669-BE25-8142BEF99FACQ47748395-0673724E-F6BF-469D-9ABD-6B182D10C55CQ50860871-E7D04F61-FE68-4F57-8A1B-7BDD92BB5B60Q50902460-C46DC497-BEEC-4E71-9FF2-53C67057116DQ52655033-F4F07FF2-D3B2-44A9-AE91-2A7B30F5D567Q54372623-668EFF19-154A-4A7C-9D5A-EA4653A378E3Q58761411-9B929C34-3BBD-404C-A761-809553B349A4Q59130134-BD6DD7F4-F560-4715-A023-996D887E7071
P2860
Mechanisms of resistance to BCR-ABL and other kinase inhibitors.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Mechanisms of resistance to BCR-ABL and other kinase inhibitors.
@en
type
label
Mechanisms of resistance to BCR-ABL and other kinase inhibitors.
@en
prefLabel
Mechanisms of resistance to BCR-ABL and other kinase inhibitors.
@en
P2093
P1476
Mechanisms of resistance to BCR-ABL and other kinase inhibitors.
@en
P2093
Allan Joaquim Lamontanara
Emel Basak Gencer
Orest Kuzyk
P304
P356
10.1016/J.BBAPAP.2012.12.009
P407
P577
2012-12-28T00:00:00Z